Recent developments in antibacterial drug discovery: Microbe-derived natural products - From collection to the clinic

Expert Opinion on Investigational Drugs

Volumn 15, Issue 3, 2006, Pages 211-226

  Leeds, Jennifer A ^a   Schmitt, Esther K ^b   Krastel, Philipp ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antibacterial drug discovery; Cell based screening; Natural products; New technologies

Indexed keywords

A 54556; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL RNA; CARRIER PROTEIN; DACTINOMYCIN; DALBAVANCIN; DAPTOMYCIN; ECO 0501; GE 23077; GLYCOSIDE; HEPTAPEPTIDE; LINEZOLID; METICILLIN; MYRAYMYCIN A1; NEOMYCIN; OPT 80; PAR 101; PEPTIDYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE; RNA 23S; SB 275833; SCH 725424; STREPTOMYCIN; TELAVANCIN; TETRACYCLINE; TIACUMICIN B; TIGECYCLINE; TRIPROPEPTIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BIODIVERSITY; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG PURIFICATION; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENTEROCOCCAL INFECTION; GENETIC ANALYSIS; HEALTH CARE DELIVERY; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PNEUMONIA; REVIEW; SEPTICEMIA; SKIN INFECTION; STRUCTURE ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL FACTORS; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33644767089     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.3.211     Document Type: Review

References (101)

1. McDONALD LA, BARBIERI LR, CARTER GT et al.: Structures of the muraymycins, novel peptidoglycan biosynthesis inhibitors. J. Am. Chem. Soc. (2002) 124:10260-10261.
2. BUTLER MS: Natural products to drugs: natural product derived compounds in clinical trials. Nat. Prod. Rep. (2005) 22:162-195.
3. HARVEY A: Natural products in drug discovery and development. IDrugs (2005) 8:719-721.
4. SCHATZ A, BUGIE E, WAKSMAN SA: Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. (1944) 55:66-69.
5. WOODRUFF HB, WAKSMAN SA: The actinomycins and their importance in the treatment of tumors in animals and man. Historical background. Ann. NY Acad. Sci. (1960) 89:287-298.
6. CLARDY J, WALSH C: Lessons from natural molecules. Nature (2004) 432:829-837.
7. BREINBAUER R, VETTER IR, WALDMANN H: From protein domains to drug candidates-natural products as guiding principles in compound library design and synthesis. Ernst Schering Res. Found. Workshop (2003):167-188.
8. EVANS BE, RITTLE KE, BOCK MG et al: Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. (1988) 31:2235-2246.
9. ALOY P, RUSSELL RB: Ten thousand interactions for the molecular biologist. Nat. Biotechnol. (2004) 22:1317-1321.
10. BREINBAUER R, VETTER IR, WALDMANN H: From protein domains to drug candidates - natural products as guiding principles in the design and synthesis of compound libraries. Angew. Chem. Int. Ed. (2002) 41:2879-2890.
11. SCHREIBER SL: Target-oriented and diversity-oriented organic synthesis in drug discovery. Science (2000) 287:1964-1969.
12. BARRETT JF: Recent developments in glycopeptide antibacterials. Curr. Opin. Investig. Drugs (2005) 6:781-790.
13. APPELBAUM PC, JACOBS MR: Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr. Opin. Microbiol. (2005) 8:510-517.
14. TORMAKANGAS L, VUORELA P, SAARIO E et al.: In vivo treatment of acute Chlamydia pneumoniae infection with the flavonoids quercetin and luteolin and an alkyl gallate, octyl gallate, in a mouse model. Biochem. Pharmacol. (2005) 70:1222-1230.
15. 2+ cleavage of 16S rRNA J. Antimicrob. Chemother. (2004) 53:592-599.
16. TUCKMAN M, PETERSEN PJ, PROJAN SJ: Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb. Drug Resist. (2000) 6:277-282.
17. LIVERMORE DM: Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother. (2005) 56:611-614.
18. MOORE IF, HUGHES DW WRIGHT GD: Tigecycline is modified by the flavin-dependent monooxygenase TetX. Biochemistry (2005) 44:11829-11835.
19. BARRETT JF: Recent developments in glycopeptide antibacterials. Curr. Opin. Investig. Drugs (2005) 6:781-790.
20. THERIAULT RJ, KARWOWSKI JP, JACKSON M et al.: Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J. Antibiot. (1987) 40:567-574.
21. SOMMA S,PIRALI G,WHITE R et al.: Lipiarmycin, a new antibiotic from actinoplanes. II. Mechanism of action. J. Antibiot. (1975) 28:543-549.
22. SONENSHEIN AL, ALEXANDER HB: Initiation of transcription in vitro inhibited by lipiarmycin. J. Mol. Biol. (1979) 127:55-72.
23. SWANSON RN, HARDY DJ, SHIPKOWITZ NL et al.: In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob. Agents Chemother. (1991) 35:1108-1111.
24. POULSEN SM, KARLSSON M, JOHANSSON LB et al.: The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Mol. Microbiol. (2001) 41:1091-1099.
25. ANCHEL M, HERVEY A, ROBBINS WJ: Antibiotic substances from Basidiomycetes+. VII. Clitocybe illudens. Proc. Natl. Acad. Sci. USA (1950) 36:300-305.
26. ANCHEL M: Chemical studies with pleuromutilin. J. Biol. Chem. (1952) 199:133-139.
27. BROTZ-OESTERHELT H, BEYER D, KROLL HP et al.: Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. (2005) 11:1082-1087.
28. MARIANI R, GRANATA G, MAFFIOLI SI et al.: Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part 3: chemical derivatization. Bioorg. Med. Chem. Lett. (2005) 15:3748-3752.
29. CICILIATO I, CORTI E, SARUBBIA E et al.: Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase I. Taxonomy, isolation and characterization. J. Antibiot. (2004) 57:210-217.
30. MCDONALD LA, BARBIERI LR, CARTER GT et al.: Structures of the muraymycins, novel peptidoglycan biosynthesis inhibitors. J. Am. Chem. Soc. (2002) 124:10260-10261.
31. RASMUSSEN BA, McDONALD L, PETERSEN P et al: Muraymycins, novel peptidoglycan biosynthesis inhibitors: identification and characterization of a natural product inhibitor of the peptidoglycan synthetic enzyme MraY. 41st Interscience Conference On Antimicrobial Agents And Chemotherapy, Chicago, USA (2001).
32. HASHIZUME H, IGARASHI M, HATTORI S et al.: Tripropeptins, novel antimicrobial agents produced by Lysobacter sp. I. Taxonomy, isolation and biological activities. J. Antibiot. (2001) 54:1054-1059.
33. HASHIZUME H, HATTORI S, IGARASHI M et al.: Tripropeptin E, a new tripropeptin group antibiotic produced by Lysobacter sp BMK333-48F3. J. Antibiot. (2004) 57:394-399.
34. ALARCO AM, WEISS K, WU Q et al.: ECO-0501, a novel anti-Gram-positive compound defining a new antibacterial structural class: preclinical evaluations. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (2004):F-719.
35. ALARCO AM, DIMITRIADOU V, McALPINE J et al.: ECO-0501, a novel anti-Gram-positive compound defining a new antibacterial structural class: mechanistic studies. 44 th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC, USA (2004):F-720.
36. SATTLER I, THIERICKE R, ZEECK A: The manumycin-group metabolites. Nat. Prod. Rep. (1998) 15:221-240.
37. YANG SW CHAN TM, TERRACCIANO J et al.: New antibiotic Sch 725424 and its dehydration product Sch 725428 from Kitasatospora sp. J. Antibiot. (2005) 58:192-195.
38. KELLER M, ZENGLER K: Tapping into microbial diversity. Nat. Rev. (2004) 2:141-150.
39. JOSEPH SJ, HUGENHOLTZ P, SANGWAN P et al.: Laboratory cultivation of widespread and previously uncultured soil bacteria. Appl. Environ. Microbiol. (2003) 69:7210-7215.
40. REICHENBACH H, HÖFLE G: Myxobacteria as producers of secondary metabolites. In: Drug discovery from nature. Grabley S, Thieriecke R (Eds), Springer-Verlag Berlin and Heidelberg GmbH & Co., Berlin, Heidelberg, New York (1999):149-179.
41. RONDON MR, AUGUST PR, BETTERMANN AD et al.: Cloning the soil metagenome: a strategy for accessing the genetic and functional diversity of uncultured microorganisms. Appl. Environ. Microbiol. (2000) 66:2541-2547.
42. SCHLOSS PD, HANDELSMAN J: Biotechnological prospects from meragenomics. Curr. Opin. Biotechnol. (2003) 14:303-310.
43. SCHLOSS PD, HANDELSMAN J: Metagenomics for studying unculturable microorganisms: cutting the Gordian knot. Genome Biol (2005) 6:229-229.
44. GILLESPIE DE, BRADY SF, BETTERMANN AD et al.: Isolation of antibiotics turbomycin A and B from a metagenomic library of soil microbial DNA. Appl. Environ. Microbiol. (2002) 68:4301-4306.
45. BRADY SF, CHAO CJ, CLARDY J: New natural product families from an environmental DNA (eDNA) gene cluster. J. Am. Chem. Soc. (2002) 124:9968-9969.
46. BRADY SF, CLARDY J: N-acyl derivatives of arginine and tryptophan isolated from environmental DNA expressed in Escherichia coli. Org. Lett. (2005) 7:3613-3616.
47. PIEL J, HUI D, WEN G et al.: Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei. Proc. Natl. Acad. Sci. USA (2004) 101:16222-16227.
48. HILDEBRANDT M, WAGGONER LE, HAIBIN L et al.: bryA: an unusual modular polyketide synthase gene from the uncultivated bacterial symbiont of the marine bryozoan Bugula neritina. Chem. Biol. (2004) 11:1543-1552.
49. SCHMIDT EW, NELSON JT, RASKO DA et al.: Patellamide A and C biosynthesis by a microcin-like pathway in Prochloron didemni, the cyanobacterial symbiont of Lissoclinum patella. Proc. Natl. Acad. Sci. USA (2005) 102:7315-7320.
50. GRABLEY S, SATTLER I: Natural products for lead identification: nature is a valuable source for providing tools. In: Modern methods for drug discovery. Hillisch R, Higenfeld R (Eds) Birkhaeuser Verlag, Basel, Switzerland (2003):87-107.
51. VUORELA P, LEINONEN M, SAIKKU P et al.: Natural products in the process of finding new drug candidates. Curr. Med. Chem. (2004) 11:1375-1389.
52. NIELSEN KF, SMEDSGAARD J: Fungal metabolite screening: database of 474 mycotoxins and fungal metabolites for dereplication by standardised liquid chromarography-UV-mass spectrometry methodology. J. Chromatogr. A (2003) 1002:111-136.
53. KOEHN FE, CARTER GT: The evolving role of natural products in drug discovery. Nat. Rev. Drug Disc. (2005) 4:206-220.
54. + ions. J. Nat. Prod. (2005) 68:385-391.
55. POTTERAT O, WAGNER K, HAAG H: Liquid chromatography-electrospray time-of-flight mass spectrometry for on-line accurate mass determination and identification of cyclodepsipeptides in a crude extract of the fungus Metarrhizium anisopliae. J. Chromatogr. A (2000) 872:85-90.
56. WENNBERG T, KREANDER K, LAHDEVUORI M et al.: Primary screening of natural products using micro fractionation combined with a bioassay. J. Liq. Chromatogr. Related Technol. (2004) 27:2573-2592.
57. DE BOER AR, LETZEL T, VAN ELSWIJK DA et al.: On-line coupling of high-performance liquid chromatography to a continuous-flow enzyme assay based on electrospray ionization mass spectrometry. Anal. Chem. (2004) 76:3155-3161.
58. CUMMINS LL, CHEN S, BLYN LB et al.: Multitarget affinity/specificiry screening of natural products: finding and characterizing high-affinity ligands from complex mixtures by using high-performance mass spectrometry. J. Nat. Prod. (2003) 66:1186-1190.
59. BLOM KF, GLASS B, SPARKS R, COMBS AP: Preparative LC-MS purification: Improved compound-specific method optimization. J. Comb. Chem. (2004) 6:874-883.
60. HARRIGAN GG, GOETZ GH: Chemical and biological integrity in natural products screening. Comb. Chem. High Throughput Screening (2005) 8:529-534.
61. ZHANG J, McCOMBIE G, GUENAT C, KNOCHENMUSS R: FT-ICR mass spectrometry in the drug discovery process. Drug Discov. Today (2005) 10:635-642.
62. MOLODTSOV SC, ELYASHBERG ME, BLINOV KA et al.: Structure elucidation from 2D NMR spectra using the StrucEluc expert system: detection and removal of contradictions in the data. J. Chem. Inf. Comput. Sci. (2004) 44:1737-1751.
63. STEINBECK C: Recent developments in automated structure elucidation of natural products. Nat. Prod. Rep. (2004) 21:512-518.
64. EXARCHOU V, KRUCKER M, VAN BEEK TA et al.: LC-NMR coupling technology: recent advancements and applications in natural products analysis. Magn. Reson. Chem. (2005) 43:681-687.
65. HUTTER B, FISCHER C, JACOBI A et al.: Panel of Bacillus subtilis reporter strains indicative of various modes of action. Antimicrob. Agents Chemother. (2004) 48:2588-2594.
66. KLEYMANN G, WERLING HO: A generally applicable, high-throughput screening-compatible assay to identify, evaluate, and optimize antimicrobial agents for drug therapy. J. Biomol. Screen. (2004) 9:578-587.
67. BRAILLARD, S, VALENTINO E, MARCHETTI A et al.: New targets for antibacterial drugs. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (2005) B-753.
68. ANKO ML, KURITTU J, KARP M: An Escberichia coli biosensor strain for amplified and high throughput detection of antimicrobial agents. J. Biomol. Screen. (2002) 7:119-125.
69. SUN D, COHEN S, MANI N et al.: A pathway-specific cell based screening system to detect bacterial cell wall inhibitors. J. Antibiot. (2002) 55:279-287.
70. FORSYTH RA, HASELBECK RJ, OHLSEN KL et al: A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. (2002) 43:1387-1400.
71. YOUNG K, JAYASURIYA H, ONDEYKA JG et al.: Discovery of FabH/FabF inhibitors from natural products using a novel strategy. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (2005):F-1844.
72. JI Y, MARRA A. ROSENBERG M, WOODNUT G: Regulated antisense RNA eliminates alpha-toxin virulence in Staphylococcus aureus infection. J. Bacteriol. (1999) 181:6585-6590.
73. HE HY: Mannopeptimycins, a novel class of glycopeptide antibiotics active against Gram-positive bacteria. Appl. Microbiol. Biotechnol. (2005) 67:444-452.
74. NICOLAOU KC, SNYDER SA: The essence of total synthesis. Proc. Natl. Acad. Sci. USA (2004) 101:11929-11936.
75. MULLER M: Chemical diversity through biotransformations. Curr. Opin. Biotechnol. (2004) 15:591-598.
76. LAMB SS, WRIGHT GD: Accessorizing natural products: adding to nature's toolbox. Proc. Natl. Acad. Sci. USA (2005) 102:519-520.
77. GANESAN A: Natural products as a hunting ground for combinatorial chemistry. Curr. Opin. Biotechnol. (2004) 15:584-590.
78. QIN CG, BU XZ, ZHONG XF et al.: Optimization of antibacterial cyclic decapeptides. J. Comb. Chem. (2004) 6:398-406.
79. LANGER T, KROVAT EM: Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr. Opin. Drug Discov. Dev. (2003) 6:370-376.
80. SHEN JH, XU XY, CHENG F et al.: Virtual screening on natural products for discovering active compounds and target information. Curr. Med. Chem. (2003) 10:2327-2342.
81. MAGNET S, BLANCHARD JS: Molecular insights into aminoglycoside action and resistance. Chem. Rev. (2005) 105:477-497.
82. SUTCLIFFE JA: Improving on nature: antibiotics that target the ribosome. Curr. Opin. Microbiol. (2005) 8:534-542.
83. WEIST S, SÜSSMUTH RD: Mutational biosynthesis-a tool for the generation of structural diversity in the biosynthesis of antibiotics. Appl. Microbiol. Biotechnol. (2005) 68:141-150.
84. SIEBER SA, MARAHIEL MA: Molecular mechanisms underlying nonribosomal peptide synthesis: approaches to new antibiotics. Chem. Rev. (2005) 105:715-738.
85. KUMAR P, KHOSLA C, TANG Y: Manipulation and analysis of polyketide synthases. Meth. Enzymol. (2004) 388:269.
86. MENZELLA HG, REID R, CARNEY JR et al.: Combinatorial polyketide biosynthesis by de novo design and rearrangement of modular polyketide synthase genes. Nat. Biotechnol. (2005) 23:1171-1176.
87. LI SM, HEIDE L: New aminocoumarin antibiotics from genetically engineered Streptomyces strains. Curr. Med. Chem. (2005) 12:419-427.
88. GRÜNFWALD J, SIEBER SA, MAHLERT C et al.: Synthesis and derivatization of daptomycin: a chemoenzymatic route to acidic lipopeptide antibiotics. J. Am. Chem. Soc. (2004) 126:17025-17031.
89. BALTZ RH, BRIAN P, MIAO V et al.: Combinatorial biosynthesis of lipopeptide antibiotics in Streptomyces roseosporus. J. Ind. Microbiol. Biotechnol. (2005) 32:1-9.
90. SHAW SJ, ABBANAT D, ASHLEY GW et al.: 15-amido erythromycins: synthesis and in vitro activity of a new class of macrolide antibiotics. J. Antibiot. (2005) 58:167-177.
91. STRATMANN A, TOUPET C, SCHILLING W et al.: Intermediates of rifamycin polyketide synthasse produced by an Amycolatopsis mediterranei mutant with inactivated rifF gene. Microbiology (1999) 145:3365-3375.
92. WEIST S, KITTEL C, BISCHOFF D et al.: Mutasynthesis of glycopeptide antibiotics: variations of vancomycin's AB-ring amino acid 3,5-dihydroxyphenylglycine. J. Am. Chem. Soc. (2004) 126:5942-5943.
93. CLARDY J: Using genomics to deliver natural products from symbiotic bacteria. Genome Biol. (2005) 6:232-232.4.
94. VELASCO A, ACEBO P, GOMEZ A et al.: Molecular characterization of the safracin biosynthetic pathway from Pseudomonas fluorescens A2-2: designing new cytotoxic compounds. Mol. Microbiol. (2005) 56:144-154.
95. WENZEL SC, GROSS F, ZHANG F et al.: Heterologous expression of a myxobacterial natural products assembly line in Pseudomonas via Red/ET recombineering. Chem. Biol. (2005) 12:349-356.
96. FREITAG A, RAPP H, HEIDE L et al.: Metabolic engineering of aminocoumarins: inactivation of the methyltransferase gene cloP and generation of new clorobiocin derivatives in a heterologous host. Chembiochem. (2005) 6:1411-1418.
97. PFEIFER BA, AMIRAAL SJ, GRAMAJO H et al.: Biosynthesis of complex polyketides in a metabolically engineered strain of E. coli. Science (2001) 291:1790-1792.
98. PEIRÚ S, MENZELLA HG, RODRÍGUEZ E et al.: Production of the potent antibacterial polyketide erythromycin C in Escherichia coli. Appl. Environ. Microbiol. (2005) 71:2539-2547.
99. RODRIGUEZ E, HU Z, OUS et al.: Rapid engineering of polyketide overproduction by gene transfer to industrially optimized strains. J. Ind. Microbiol. Biotechnol. (2003) 30:480-488.
100. ASKENAZI M, DRIGGERS EM, HOLTZMAN DA et al.: Integrating transcriptional and metabolic profiles to direct the engineering of lovastatin-producing fungal strains. Nat. Biotechnol. (2003) 21:150-156.
101. STUTZMAN-ENGWALL K, COLON S, FEDECHKO R et al.: Semi-synthetic DNA shuffling of aveC leads to improved industrial scale production of doramectin by Streptomyces avermitilis. Metab. Eng. (2005) 7:27-37.